A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
Study of Drug in Patients with Progressive Supranuclear Palsy
Sponsor: AbbVie, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR2561
U.S. Govt. ID: NCT02985879
Contact: Evelyn D. Dominguez: 212-305-2371 / edd5@cumc.columbia.edu
Additional Study Information: This is a study for persons with a diagnosis of Progressive Supranuclear Palsy, involving an experimental treatment.
This study is closed
Investigator
Lawrence Honig, MD, PhD
Do You Qualify?
Are you 40 years of age or older? Yes No
Do you have Progressive Supranuclear Palsy (PSP)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Evelyn D. Dominguez
edd5@cumc.columbia.edu
212-305-2371
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE